Long-Term Safety and Effectiveness of Mepolizumab 300 mg in Europe (Mepo LTF Study) | MicrobiomeTrials← Back to trialsNCT07591753
Long-Term Safety and Effectiveness of Mepolizumab 300 mg in Europe (Mepo LTF Study)
CompletedOBSERVATIONAL
Trial Details
Start: 2025-09-18Est. Completion: 2026-03-31
Enrollment target: 591 participants Locations- University of Florence, Florence, Florence, Italy
Other microbiome trials you might be interested in
Eosinophilic Granulomatosis With Polyangiitis (EGPA)
This is a multicenter, retro-prospective observational study evaluating the effectiveness and safety of benralizumab in …
Florence, ItalyEst. completion Feb 11, 2027
Eosinophilic Granulomatosis With PolyangiitisChurg-Strauss Syndrome
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune system disorder that causes asthma, an excessive n…
San Diego, United StatesEst. completion Dec 2028